Published

Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [C]MDL100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in neuroergonomics
Date: 2021-01-01
Source: PubMed
DOI: 10.3389/fnrgo.2021.784576
PubMed: 38235248

Authors

Barrett FS Zhou Y Carbonaro TM Roberts JM Smith GS Griffiths RR Wong DF

Watch author

Derived topics and classifications

psilocybin Addiction Brain Imaging Pharmacology Receptor Pharmacology Default Mode Network Healthy Volunteers Other

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine2026-05-01 Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [C]MDL100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation.2021-01-01

Related papers

Psilocybin therapy: A novel approach to treating depressionInternational Journal of Surgery Global Health · 2023-06-02 Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-08-14 Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05 A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-06-08 Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingClinicalTrials.gov · 2026-06-05 Open Label Psilocybin Brain Stimulation and Imaging Pilot StudyClinicalTrials.gov · 2026-08-07 Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy ParticipantsClinicalTrials.gov · 2025-06-12